Mr. Small is a member of our Board of Directors and serves as a senior advisor. He is a co-founder of Assembly and served as President and Chief Executive Officer from 2015 to 2019. Currently, Mr. Small is Managing Director of Luson Bioventures, a biopharmaceutical venture creation firm that he founded in 2007. Previously, he served as a founding director, President and Chief Executive Officer of Naurex, which was acquired by Allergan in 2015. Naurex's preclinical programs formed the basis for a spinout CNS company, Aptinyx, that completed an IPO in 2018. Mr. Small also served as a founding director, President and Chief Executive Officer of Coferon and Assembly Pharmaceuticals, and has helped to launch and advance several other biotechnology companies. Many of these companies are portfolio enterprises of Luson Bioventures. Mr. Small received a BS in Business from Franklin College and studied global business at the Harlaxton College affiliate program in England.